Medical World News® After Hours: Oncologist Amy Comander, MD, Discusses Marathon Running and Motivation

Video

During an After Hours segment of Medical World News®, Amy Comander, MD, spoke about her passion for marathon running and how it helps keep her inspired in her work as an oncologist.

A recent ‘Narratives in Oncology’ article written for The Oncologist journal details the experience of physician and marathon runner Amy Comander, MD, with the 124th Boston Marathon. Like most events scheduled in 2020, the marathon was canceled due to the COVID-19 pandemic. In her narrative, Comander discusses gratitude and resilience in times of uncertainty, explaining how the running community has helped her remember to keep her head up.

In addition, Comander has helped organize fundraising races, like the PAVING Program 5K, a virtual 5k to be held June 4 through 6, 2021.

CancerNetwork® sat down with Comander, of the Mass General Cancer Center in Waltham and Harvard Medical School, to talk about what marathon running means to her and her plans for participating in future races.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

References

1. Comander A. Remember Your Why: An Oncologist's Reflections on Running During the COVID-19 Pandemic. Oncologist. 2021;26(4):348-349. doi:10.1002/onco.13683

Recent Videos
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
In considering patients’ busy lives, AI may help reduce the number of visits required to fully stage and grade cancers.
Related Content